<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169377</url>
  </required_header>
  <id_info>
    <org_study_id>P030422</org_study_id>
    <nct_id>NCT00169377</nct_id>
  </id_info>
  <brief_title>Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD)</brief_title>
  <official_title>Study of the Effects of High Frequency Stimulation of the Subthalamic Stimulation in the Treatment of Severe Obsessive-compulsive Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marie-laure Welter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obsessive-compulsive disorder is a disabling and frequent disorder. In some patients, the
      medical treatment is ineffective. The pathophysiology of this disease is still unknown. Some
      data suggest that basal ganglia dysfunction could participate in the occurrence of OCD. The
      aim of this study is to evaluate the efficacy of subthalamic nucleus high-frequency
      stimulation in patients with severe OCD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale-Brown-Obession and Compulsion Scale (YBOCS)</measure>
    <time_frame>2 three-month periods</time_frame>
    <description>YBOCS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global assessment of function (GAF)</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>GAF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression(CGI)</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>CGI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery and Asberg Depression Rating scale (MADRS)</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>MADRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression scale (HAD-S)</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>HAD-S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>SDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Scale for Anxiety (BABS)</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>BABS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Adjustment scale self-report (SAS-SR)</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>SAS-SR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuropsychological tests</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>STROOP, apathy scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>10 month follow-up but 2 3-month period for the cross-over</time_frame>
    <description>adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Yale-Brown-Obession and Compulsion Scale (YBOCS)</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of function (GAF)</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression(CGI)</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery and Asberg Depression Rating scale (MADRS)</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression scale (HAD-S)</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Adjustment scale self-report (SAS-SR)</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuropsychological tests</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulation parameters</measure>
    <time_frame>observational follow-up at 22 month, 34 month and 46 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep brain stimulation on followed by off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No stimulation, deep brain stimulation off followed by on</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>deep brain stimulation</intervention_name>
    <description>Stimulator on followed by off</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No stimulation</intervention_name>
    <description>Stimulator off followed by on</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe obsessive-compulsive disorder

        Exclusion Criteria:

          -  Contraindication to magnetic resonance imaging (MRI)

          -  Severe cognitive or behavioral disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Mallet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique-Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Anne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Marie-laure Welter</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Obsessive compulsive disorder</keyword>
  <keyword>deep brain stimulation</keyword>
  <keyword>subthalamic nucleus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

